IGF-1 LR3 (Long Arg3-IGF-1) is a synthetic research analog of human insulin-like growth factor 1 (IGF-1), the 70-amino-acid hormone the liver produces in response to growth hormone signaling. The analog extends that native sequence with a 13-amino-acid addition at the N-terminal end and substitutes arginine for glutamic acid at position 3, bringing the total chain length to 83 amino acids.
This is not a naturally occurring hormone — it does not circulate in the human body under normal physiology. It was engineered specifically as a laboratory tool, and its name reflects its defining structural feature: a "long," extended N-terminus carrying an "Arg3" substitution, hence Long Arg3-IGF-1, or IGF-1 LR3 for short.
Native IGF-1 does not act freely in circulation. More than 90% of it is bound at any moment to a family of IGF-binding proteins (IGFBPs), which regulate how much of the hormone is available to interact with cell-surface receptors. This is essential for normal endocrine regulation, but it is an obstacle for researchers who want to study sustained IGF-1 receptor activity in a controlled experimental system, because native IGF-1 added to a culture is rapidly sequestered.
IGF-1 LR3's N-terminal modification sits directly in the region IGFBPs use to recognize and grip IGF-1, disrupting that interaction without touching the separate region of the molecule responsible for receptor binding. The practical result, documented across published in-vitro binding studies, is an analog that stays "free" and biologically available for a much longer window than native IGF-1 does in the same system.
The IGF-1 receptor is a transmembrane tyrosine kinase receptor, structurally related to the insulin receptor. When IGF-1 — native or LR3 — binds it, the receptor dimerizes and undergoes autophosphorylation, triggering intracellular cascades including the PI3K/Akt and Ras/MAPK pathways. These cascades are documented in the literature as central to cell growth, proliferation, and survival signaling.
Because IGF-1 LR3's structural changes are positioned away from the receptor-binding interface, published research reports that it retains receptor-engagement activity broadly comparable to native IGF-1. Its research value comes almost entirely from its extended availability, not from any change to how it interacts with the receptor itself.
IGF-1 LR3 shows up in published in-vitro and preclinical research spanning cell proliferation assays, muscle-cell biology, and studies of insulin-receptor crosstalk, generally wherever a study design calls for prolonged IGF-1 receptor stimulation rather than a brief pulse of exposure. It is treated in this literature purely as a research reagent — a tool for isolating and studying a signaling pathway, not a therapeutic candidate.
It has never advanced through any pharmaceutical development or approval pathway, and it is not approved for human or veterinary use anywhere. Its entire documented history relates to laboratory use in cell-culture and animal-model research settings.
This overview is published because IGF-1 LR3 is a name that circulates widely in general peptide discussion, and REVIVE LAB UAE would rather provide an accurate, research-grounded explanation than leave that gap to less reliable sources. It is general structural and mechanistic information only — not a recommendation, endorsement, or guide to use.
IGF-1 LR3 is not part of REVIVE LAB UAE's catalog and cannot be purchased on this site. Readers interested in REVIVE LAB UAE's actual research-peptide offerings, including compounds like Tesamorelin that work in the same general growth-hormone axis, can view the current catalog directly.